Eosinophilic Esophagitis
Conditions
Brief summary
Eosinophilic esophagitis (EoE) is characterized by allergy-driven inflammation of the esophagus leading to a variety of gastrointestinal symptoms and increased healthcare utilization. While considered a rare disease, EoE is rapidly increasing in prevalence in the United States. Treatment options are limited and include dietary modifications with the elimination of suspected food triggers or pharmacological options including proton pump inhibitors (PPIs) and swallowed corticosteroids. Compliance to strict elimination diets is difficult thus many patients elect to use swallowed corticosteroids. Because nearly half of all EoE patients are treated with swallowed corticosteroids there is a growing concern regarding the long-term effects of this class of medication.4 It is known that oral corticosteroids can compromise bone mineral density and growth velocity5-7. Furthermore, there have been multiple studies exploring the relationship between inhaled corticosteroids (ICS) and endocrine effects in asthmatics. While the risk of ICS use is less compared to systemic corticosteroids, higher ICS doses do cause deleterious effects on growth and bone health8-11. Currently, there are no published studies examining the effect of swallowed corticosteroids on bone mineral density or growth velocity in patients with EoE. Given the route of administration, there may be more systemic absorption leading to a higher risk of long-term complications. The proposed work will address the following specific aims: Specific Aim 1: Assess effects of swallowed corticosteroids on bone mineral density (primary outcome) in children 5-12 years of age with EoE compared to age matched controls. Specific Aim 2: Evaluation of the effect of swallowed corticosteroids on growth velocity.
Interventions
DIAGNOSTIC_TESTBone Mineral Density (DEXA) scan
Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
DIAGNOSTIC_TESTVitamin D Measurement
Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
DIAGNOSTIC_TESTHeight measurement
Height will be measured at baseline and 12 months.
OTHERAssessment of medication compliance
Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
Sponsors
University of Arkansas
Arkansas Children's Hospital Research Institute
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to 12 Years
Inclusion criteria
* Intervention: 1. Age 5-12 years 2. Diagnosis of EoE based upon a peak eosinophil count of ≥ 15 eosinophils/high powered field (hpf) on at least one esophageal biopsy while on a minimum of 8 weeks of PPI therapy 3. Patient/Family has elected to start swallowed corticosteroids for the treatment of EoE with a minimum daily dose of at least 0.5 mg budesonide or 440 mcg fluticasone. The decision to start swallowed corticosteroids will be made based upon the judgement of the provider, potential subject, and family during a clinic visit and will not be part of the research procedures. * Controls: 1. Age 5-12 years 2. Followed in the ACH allergy clinic, but not required to have a diagnosis of EoE 3. Not treated with swallowed corticosteroids
Exclusion criteria
* Intervention and controls: 1. Non-English speaking 2. Patients actively taking systemic corticosteroids or previous use of systemic corticosteroids within the past 6 months 3. Patients actively taking inhaled corticosteroids or prior use of inhaled corticosteroids in the 6 months prior to screening 4. Current or previous treatment with swallowed corticosteroids for EoE at the time of screening 5. Osteopenia or osteoporosis on baseline dual energy X-ray absorptiometry (DEXA).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effects of swallowed corticosteroids on bone mineral density | 12 months | Change in bone mineral density over 1 year while being treated with swallowed corticosteroids compared to age-matched controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects of swallowed corticosteroids on linear growth | 12 months | Changes in linear growth over 1 year while being treated with swallowed corticosteroids compared to controls |
Countries
United States
Outcome results
None listed